Nested Therapeutics
43 posts
Nested Therapeutics
@nestedtx
Nested aims to advance precision oncology medicine by finding new driver mutations hiding in plain sight to reach a broader group of patients.
Cambridge, Massachusetts Katılım Mart 2022
11 Takip Edilen121 Takipçiler
Today at #AACR2026: Dr. Tarhini is presenting initial Phase 1 NST-628 dataset
nestedtx.com/wp-content/upl…
English
Two years after unveiling NST-628 at AACR’s New Drugs on the Horizon and in Cancer Discovery, we're excited to share preliminary Phase 1 data for our novel, fully brain-penetrant, pan-RAF/MEK molecular glue at #AACR26 in San Diego. nestedtx.com/wp-content/upl…
English
Nested Therapeutics retweetledi
Watch first author Meagan B. Ryan discuss her research article, NST-628 is a novel and potent pan-RAF-MEK inhibitor, published simultaneously at #AACR24:
vimeo.com/932606757/4d0b…
@nestedtx
Cancer Discovery@CD_AACR
Just published with the #AACR24 New Drugs on the Horizon presentation— The pan-RAF-MEK Non-degrading #MolecularGlue NST-628 Is a Potent and Brain-penetrant Inhibitor of the RAS-MAPK Pathway with Activity Across Diverse RAS- and RAF-driven Cancers bit.ly/3Jbh9mh @nestedtx
English
Nested Therapeutics retweetledi
AACR24: Having entered the clinic last night, @nestedtx's CEO discusses the preclinical profile of a brain-penetrant, pan-RAF/MEK molecular glue. #AACR24
Full video: biotechtv.com/post/nested-th…
English
Our CSO, @ Klaus Hoeflich, recently sat down with @ Sally Church on Nested’s progress. Check out the interview on Biotech Strategy Blog and discover our impressive journey from concept to clinic in just three years. #NST628 #NestedTherapeutics #biotech
biotechstrategyblog.com/2024/04/transl…
English
Nested Therapeutics retweetledi
FDA clears @nestedtx Nested Therapeutics' IND application for NST-628, a promising treatment for solid tumors. #oncology #cancerresearch #FDA #FDANews #OncWeekly buff.ly/4cCnhBI
English
Nested Therapeutics retweetledi
Just published with the #AACR24 New Drugs on the Horizon presentation—
The pan-RAF-MEK Non-degrading #MolecularGlue NST-628 Is a Potent and Brain-penetrant Inhibitor of the RAS-MAPK Pathway with Activity Across Diverse RAS- and RAF-driven Cancers
bit.ly/3Jbh9mh
@nestedtx
English
Nested Therapeutics retweetledi
Congratulations to Klaus Hoeflich and co-authors at @nestedtx on this simultaneous #AACR24 publication in @CD_AACR!
Cancer Discovery@CD_AACR
Just published with the #AACR24 New Drugs on the Horizon presentation— The pan-RAF-MEK Non-degrading #MolecularGlue NST-628 Is a Potent and Brain-penetrant Inhibitor of the RAS-MAPK Pathway with Activity Across Diverse RAS- and RAF-driven Cancers bit.ly/3Jbh9mh @nestedtx
English
Yesterday at AACR, we unveiled the preclinical data on our lead program, NST-628, during an oral presentation as part of the “New Drugs on the Horizon” series. For more insights, visit our website and stay tuned for more updates!
nestedtx.com/wp-content/upl…
English
We're proud to announce the FDA clearance of our IND Application for NST-628. Additionally, our CSO, will present pre-clinical data on NST-628 at the “New Drugs on the Horizon” Series at the 2024 AACR Annual Meeting. Stay tuned for more updates! nestedtx.com
English
Today, we announce the appointment of three members to our board of directors. “We look forward to partnering with them as we continue to build our pipeline and advance our first program into the clinic this year.” - Darrin Miles, CEO
nestedtx.com/wp-content/upl…
English
We are thrilled to share we’ve been recognized in BioSpace's prestigious NextGen Bio Class of 2024 of the hottest new life sciences companies. Cheers to an extraordinary journey ahead! #NextGen2024 #Innovation
Learn more here: biospace.com/article/nextge…
English
Nested Therapeutics retweetledi
Our list of the best R&D-intensive startups spun out of universities in 2022 includes companies correcting misfolded proteins, creating second-generation GPCR agonists and mining cancer genomes for novel targets #NBTAcademicStartups go.nature.com/3RyvVZA
rdcu.be/ds1XJ
English
We're excited to be featured in “Precision Oncology News” highlighting our co-founders, innovative platform and growing pipeline. Our lead compound NST-628, is anticipated to enter clinical trials in early 2024. Read more about us & the compelling science here!
English
Happy #Thanksgiving from all of us at Nested Tx!
As we head into the holiday season, let's take a moment to unwind and reflect on the impactful contributions we make every day. May this time be filled with relaxation, joy, and moments of #gratitude with loved ones!
English
Exciting news! @NewEnglandVC is set to host its 11th Annual NEVYs, and we've just received a nomination for the Emerging Life Science Company of the Year award!
Curious to find out the results? Join us on December 7th at thenevys.com! 🏆 #NEVYs23 #LifeScienceAward
English
We are #hiring! This position will be responsible for developing and preparing global regulatory strategies for multiple programs.
Reach out to learn more about us and our unique platform at careers@nestedtx.com!
#precisiononcology #clinicaldevelopment #biotech
English
A huge round of applause to our presenters for an exceptional job representing Nested Therapeutics at the AACR-NCI-EORTC Conference in Boston! The team’s passion, expertise and dedication shined through as they showcased our strides made with NST-628.
#PrecisionMedicine
English
You can learn more about it here: nestedtx.com/wp-content/upl…
English
Today, at the 2023 AACR-NCI-EORTC Conference, we unveiled the first preclinical data on the mechanism of action, efficacy and brain penetrance of our lead candidate, NST-628, a mechanistically novel non-degrading molecular glue targeting multiple nodes in the RAS/MAPK pathway.
English